南京包代生生孩子多少钱

择要

胎儿发展受限，也称为胎儿宫内发展受限，是一种怀胎的罕见并发症，与多种不良的围产期终局有关。现阶段，胎儿发展受限的专业术语，病因学跟诊断尺度尚无共鸣，发展受限的胎儿的最好。另一个应战是难以划分实质小但能实现其发展潜力的胎儿跟因为潜伏的病理情况而不克不及知足其发展潜力的小胎儿。本文致力于于便胎儿发展受限的专业术语、病因学、诊断、监测手腕，和孕期。

靠山

专业术语

关于未能到达畸形体重的胎儿跟未能到达畸形诞生体重的新生儿分类的术语是分歧的。利用定义明确的术语可能增进产科医生跟新生儿科医生之间的相同，这些术语依据给定孕龄的相对体重或体重百分位数来描写胎儿跟新生儿体重[1-4]。正在本文中，“胎儿发展受限”这一术语将用于描写估量胎儿体重小于同胎龄体重的第10百分位的胎儿，而术语“小于胎龄儿（SGA）”仅用于描写诞生体重小于同胎龄的第10百分位的新生儿。

发病率

胎儿发展受限的发病率在于本地采取的的界说。如前所述，正在美国，胎儿发展受限利用最普遍的界说是估量胎儿体重小于同胎龄体重的第10百分位数[5]。然而，该界说不思量到每一个胎儿的个体化发展潜力，而且发展潜力的较大胎儿，由此能够惹起不良的产科终局。相反，这一界说也能够将一些体质上较小的胎儿误诊为胎儿发展受限[6-9]。为了更精确天评价新生儿跟胎儿是不是畸形发展，研讨职员计划出了计较个体化发展尺度的公式[1011]。但现阶段还没有证明利用这些公式可能改良产科终局。

病因

胎儿发展受限的病因大抵可以分为母体，胎儿跟胎盘因素（见表1）。只管分歧因素惹起胎儿发展受限的次要病理生理机制分歧，但它们经常（但并不是皆是）存在不异的终极演化道路：子宫-胎盘灌注不良及胎儿营养不良。

母体疾病

能够招致胎儿发展受限或SGA的母体疾病包罗任何与血管疾病相关的慢性疾病[12-14]，如怀胎相关的高血压疾病[12]。抗磷脂综合征是一种获得性免疫介导的血栓造成疾病，也可惹起胎儿发展受限[15]。然而，遗传性血栓造成疾病，包罗因子V莱顿（Leiden）渐变、凝血酶原渐变，或亚甲基四氢叶酸还原酶基因突变等，均未被发现与胎儿发展受限或SGA相关[16-18]。

药物的利用跟滥用

孕期抽烟可以使SGA危险增长3.5倍，是个可转变的危险因素[1219]。别的可以惹起SGA的因素包罗酒精、可卡因跟镇痛剂[20-25]。即便天天只摄入一至两杯含酒精的饮料，产生SGA的危险也会增长[21]。

孕期养分

纵向研讨评释，母亲的营养不良与SGA之间存在必然接洽[2627]。这些研讨显现，怀胎26周前极低的蛋白质摄入量与SGA相关，严峻的热量限定可以惹起诞生体重必然水平的降低。可是，当母亲不营养不良而思疑归并胎，不明白证据评释，额定的增长孕期养分摄入可能增长胎儿体重或改良预后[28]。

多胎怀胎

正在美国，双胎怀胎虽然仅占活产儿的2-3％，但产生新生儿不良终局的概率高达10-15％，而且与早产跟SGA的发生率增长有关[29-31]。据报导，正在多胎怀胎中，双胎怀胎产生SGA的危险高达25％，而三胎跟四胎怀胎产生SGA的危险高达60％[32]。另外，单绒毛膜双胎怀胎因为存在胎盘分派没有平衡和双胎输血综合征，较易产生SGA[33]。

致畸剂裸露

某些孕期药物也与胎儿发展受限有关。药物对胎儿的影响在于药物本身的致畸性、、药物的剂量跟药物代谢的个别易感性。某些抗肿瘤药物（如环磷酰胺）、抗癫痫药物（如丙戊酸）跟抗血栓药物（如华法林）的利用与胎儿发展受限危险的增长有关[34-38]。

传染性疾病

据估计，约5-10％的胎儿发展受限次要是因为宫内熏染惹起的[39]。此中，正在全世界规模内，疟疾是最次要的病因[40]。其他与胎儿发展受限有关的流行症包罗巨细胞病毒，风疹，弓形虫病，水痘跟梅毒[3941-44]。

遗传跟结构性疾病

胎儿发展受限与某些染色体异常有关：至少有50％的13-三体或18-三体的胎儿归并胎儿发展受限[45]。经由过程绒毛取样判定的限制性胎盘嵌合体也与胎儿发展受限有关[4647]。

存在多种类型的布局畸形（但没有存在染色体或遗传异常）的胎儿，产生胎儿发展受限的危险也会增长[48]。例如，与畸形的胎儿跟新生儿比拟，得了先天性心脏病的胎儿跟新生儿产生胎儿发展受限跟SGA的危险均增长[4950]。先天性腹裂是另一种较常惹起胎儿发展受限的畸形，约25%的先天性腹裂的胎儿归并胎儿发展受限[51]。

胎盘疾病跟脐带异常

胎儿发展受限最罕见的病理机制是因为胎盘造成异常招致的胎盘灌注不良（即胎盘功用不全）[52]。某些胎盘疾病（如，胎盘早剥、胎盘梗死、轮状胎盘、血管瘤跟绒毛膜血管瘤）跟脐带异常（如，脐带帆状附着跟脐带边缘拔出）与胎儿发展受限的产生也有必然关联[3453-57]。然而，其他胎盘疾病，如胎盘植入跟前置胎盘，与胎儿发展受限无较着关联[58]。

约莫有1％的怀胎存在单脐动脉[59]。没有伴随别的解剖学或，有研讨认为单脐动脉的存在与胎儿发展受限有关，但此外一些研讨则认为无相关性[6061]。

围产期发病率跟死亡率

胎儿发展受限会增长胎儿宫内死亡率、新生儿发病率跟新生儿殒命的危险[62]。另外，流行病学研讨评释，发展受限的胎儿出缓，成年后也简单患病（如瘦削，2型糖尿病，冠状动脉疾病跟中风）[6364]。

胎儿发展受限显著增长逝世产危险，发展受限水平越严峻的胎儿，产生危险越大[65]。胎儿体重低于同孕龄体重的第10，胎儿殒命的危险约为1.5％，约是畸形体重胎儿的两倍。相比之下，低于同孕龄体重第5百分位的胎儿产生死产的危险增加到2.5％[6667]。归并脐动脉舒张末期血流缺失或许颠倒的发展受限的胎儿，产生不良终局的危险增长，新生儿死亡率跟发病率亦增长[68]。

小于胎龄儿的新生儿易得以下并发症，包罗低血糖，下胆红素血症，体温太低，脑室内出血，坏死性小肠结肠炎，癫痫发生发火，败血症，呼吸拮据综合征跟新生儿殒命[69-73]。

筛查胎儿发展受限

病史跟体格检查

怀胎24-38周，丈量的宫底高度（厘米），用于估量孕龄和挑选低于或跨越畸形体重第10百分位的胎儿发展[74]。据报导，怀胎32-34，单一宫底高度的丈量检出胎儿发展受限的敏感性约为65-85％，特异性约96％[75-79]。宫底高度作，其准确性遭到母体瘦削跟归并子宫平滑肌瘤等因素的限定，而超声是更好的搜检手腕。

超声诊断跟评价

为了评价胎儿发展受限，平常利用四种生物丈量目标：1）双顶径，2）头围，3）腹围，跟4）股骨长度。这些丈量目标可以组合去估量胎儿体重[80]。95％的胎儿估量体重能够偏离诞生体重高达20％，而此外5％的估量体重误差以至能够跨越20％[7881-83]。若是超声估量胎儿体重低于同孕龄体重的第10百分位，则应思量进一步搜检，例如羊水评价跟脐动脉多普勒血流评价。因为发展受限的胎儿易归并遗传跟布局疾病，若是初期未行搜检，也发起止胎儿解剖学的超声搜检。

胎，多普勒血流测速，特别是对脐动脉的评价，其功效曾经失掉了普遍的研讨跟回想剖析[84]。脐动脉舒张末期血流缺失或颠倒与围产儿殒命危险增长有关[85-88]。胎儿发展受限的尺度产前检测中增长脐动脉多普勒血流测速名目，围产儿死亡率降低可多达29％[8990]。静脉导管中的血流丈量也可测验考试用于评价胎儿形态，但还没有证明其可能改良产科终局[91-94]。

临床注意事项跟发起

孕期应若何筛查胎儿发展受限？

一切妊妇均应回想产科病史，发明胎儿发展受限的危险因素。怀胎24周后，每次产检均应丈量宫底高度。测得宫底高度对应孕周与实际孕周差值大于3者，能够存在胎儿发展受限[74]。母亲瘦削、多胎怀胎及归并子宫肌瘤会影响宫底高度的评价；屡次怀胎或宫底高度，优选超声搜检。当存在增长胎儿发展受限危险，也可以利用超声搜检。

只管另有其他筛查胎儿发展受限的方式（包罗孕晚期体系超声筛查、子宫动脉多普勒血流测速，和怀胎相关血浆卵白A的剖析丈量），但不证据评释上述这些筛查手腕可能改良产科终局[95-102]。

若何评价有上次小于胎龄儿临盆史的妊妇？

SGA诞生的复发危险约为20％[9]。任何有上次SGA临盆史的妊妇皆应回想其既往病史，以发明危险因素，特别是可纠正的危险因素。只管还没有肯定最好监测计划，但关于那类妊妇有需要停止接连的超声搜检去评价胎儿发展环境。若是妊妇此次怀胎的胎儿发展环境畸形，上次SGA临盆史则不是停止产前胎心率测试，胎儿生物物理评分或脐动脉多普勒血流测速的指征[103]。

其他与SGA相关的母体因素亦须要被评价。抗磷脂综合征的一个诊断尺度是上次怀胎于34周前临盆形态学畸形的发展受限的胎儿。然而，不充足的证据评释正在随后的怀胎中停止筛查跟医治可以改良产科终局[104]。遗传性血栓造成偏向的杂合性（如因子V莱顿（Leiden）渐变跟凝血酶原渐变）并未一直与胎儿发展受限相关，且并没有推举对母亲停止血栓造成偏向的相关检测[17104]。

胎儿发展受限若何防备？

现已有较多方式去防备胎儿发展受限。许多养分跟膳食增补战略已被研讨，只管尚无一种无效。这些方式包罗个体化养分征询[105]；增长鱼类，低脂肪肉类，谷物，生果跟蔬菜的摄入量[106]；低盐饮食[107]；增补铁[108]，锌[109]，钙[110]，蛋白质[111]，镁[112]跟维生素D[113]。是以，养分跟膳食增补战略不克不及防备胎儿发展受限，故没有推举。

一样，尚无同等的证据评释住院或门诊卧床苏息可以防备胎儿发展受限或降低SGA的出生率[114]。关于有SGA临盆史的妊妇，一些专家建议利用阿司匹林去防备胎盘功用不全。可是，不充足证据证实这类医治防备胎儿发展受限的通例手腕[115-118]。

胎儿死，断检测？

只管零丁的胎儿发展受限能够与非整倍体胎儿相关，但若是存在胎儿布局异常，非整倍体的危险也会增长。是以，胎儿发展受限跟，患者应停止胎儿异常类型征询，并思量停止产前诊断测试。此外，因为怀胎初期发明的胎儿发展受限更多见与非整倍体的产生相关[119]，是以孕中期发明的胎儿发展受限是停止遗传征询跟产前诊断检测的指征。

若何评价跟经管怀胎归并胎儿发展受限？

超声搜检依然是评价发展受限胎儿的最好方式。监测胎儿发展受限的方式包罗胎儿生物丈量跟羊水量的接连超声丈量。思量到围产期好处，脐动脉多普勒血流测速跟临盆前监测（如非应激实验或或许胎儿生物物理评分）发起正在到达可以临盆的孕周停止[3031120-124]。评价胎儿发展还没有肯定。大多数发展受限的胎儿可以经由过程每3-4周的接连超声监测失掉充足评价。因为超声丈量本身的固有偏差会影响最胎儿阶段发展的精确评价，是以超声评价2周[125126]。

多普勒血流测速仪正在评价怀胎归并胎儿发展受限方面有何作用？

脐动脉多普勒血流测速正在怀胎归并胎儿发展受限的诊断跟经管中起紧张作用。它与尺度胎儿监测（如非应激实验，生物物理学表面，或二者联合）的结合利用，可以改良已确诊发展受限胎儿的诞生终局[90]。多普勒评价可以发明胎儿发展受限的病因，由于脐动脉血流阻力增长评释怀胎归并潜伏的胎盘功用不全。另外，脐动脉舒张末期血流缺失或颠倒与围产期胎儿殒命增长相关[86-88127]，而且可以影响胎儿发展[84]。多普勒血流测速对胎儿其他血管，包罗对大脑中动脉跟心前区静脉体系的评价也被用来研讨胎儿发展受限的产生。正在欧洲脐带跟胎儿血流的随机实验（TRUFFLE）研讨的2年随访中，研讨职员发明，与孕期多普勒追踪胎儿心率变更临盆的胎儿比拟，只管孕期多普勒监测静脉导管晚期变更能够招致围产期胎儿跟婴儿的死亡率增长，但其与儿童2少有关[128]。是以，这些血流丈量还没有被证明可能改良围产期终局，而且它们正在临床中的作用仍不确[9192127129-131]。

？

胎儿发展受限受限的潜伏病因（若是已知），估量胎龄跟其他产前检查的成果，例如，转变染色体非整倍体胎儿或归并先天性熏染的。另外，正在某些环境下，妊妇能够会取舍没有干涉干与，例如，即便胎儿殒命危险增长，一些妊妇也能够取舍抛却严峻发展受限的胎儿，而正在25。可以经由过程个性化跟多学科的方式增强产前经管。当怀胎干涉干与是围产期受益，产前胎儿监测能够有助。零丁的胎儿发展受限不是剖宫产临盆的指征，临盆方法的取舍应基于其他临床前提。

胎儿发展受限干涉干与实验是现阶段独一宣布的，用来评价发展受限的初期早产儿（小于34周）。正在这项实验中，当关于怀胎归并胎儿发展受限的妊妇，产科医生没有肯定分，妊妇则被随机分派到初期临盆组（48）或等候医治组（停止产前监测，直到不再需）。两组的倍他米紧给药率不异。结果显示，两组的围产儿存活率类似，而且正在6-12岁的随访中发明，两组妊妇临盆的胎儿正在认知、语言、行动或运动才能方面不差别[132-134]。正在长时间不成比例宫内发展干涉干与实验中，单胎怀胎36或以上的思疑胎儿发展受限（界说为估量胎儿体重低于第10百分位）的妊妇被随机分派到临盆组或许等候医治组（当出）[135]。只管该行列研讨样本量太小，不足以肯定个别终局（如围产儿殒命）是不是遭到分歧处置惩罚方式的影响，但那两组之间的新生儿整体终局不差别。

现阶段不充足无力的随机实验去肯定孕周为34-36周的发展受限的胎儿。根识，尤尼斯·肯尼迪·施莱佛国立儿童安康与人类开展研究所、美国母婴医学学会跟美国妇产科学院的结合集会针对已确诊的胎儿发展受限，给出以：1）怀胎仅归并胎，发起怀胎380/7周-396/7周临盆；2）胎儿发展受限归并其他惹起不良产科终局的危险因素（如羊水过少，脐动脉多普勒血流测速成果异常、产妇自身因素，或有其他合并症），发起怀胎320/7周至376/7周临盆。正在某些严峻环境下，如脐动脉舒张末期血流颠倒，正在此孕周规模内也应提早停止怀胎[136-138]。

胎儿发展受限的妊妇，估量正在怀胎34，应正在新生儿重症监护室中间停止临盆，最好征询母婴专家后停止临盆。估量正在怀胎336/7，糖皮质激素因为与改良新生儿早产终局有关，发起正在临盆前利用。另外，妊妇估量正在怀胎340/7周至366/7，若妊妇能够正在7天内临盆，或已利用过糖皮质激素，也发起临盆前利用糖皮质激素[139-143]。关于能够正在怀胎32周前临盆的妊妇，应利用硫酸镁用于胎儿跟新生儿的神经护卫[144-147]。

总结跟论断

以下发起跟论断基于优越跟同等的迷信证据（A级）：

脐动脉多普勒血流测速与尺度胎儿监测（如非应激实验、生物物理评分，或二者联合）的结合利用，可以改良已诊断发展受限的胎儿的产科终局。

若是估量正在怀胎336/7周之前临盆，糖皮质激素因为与改良早产新生儿终局有关，推举临盆前利用。另外，另外，妊妇估量正在怀胎340/7周至366/7，若妊妇能够正在7天内临盆，或已利用过糖皮质激素，也发起临盆前利用糖皮质激素。

估量正在怀胎32周前临盆，应推举利用硫酸镁用于胎儿跟新生儿的神经护卫。

养分跟膳食增补战略不克不及防备胎儿发展受限，没有推举利用。

以下发起跟论断基于共鸣跟专家定见（C级）：

零丁的胎儿发展受限不是剖宫产临盆的指征。

胎儿发展受限受限的潜伏病因（若是已知），估量胎龄跟其他产前检查的成果。

发起的绩效衡量

思疑归并胎儿发展受限的妊妇，若是正在确诊后不停止临盆，则启动评价跟监测胎儿发展跟安康的筹划，并统计（那一部分妊妇所占的）比例。

参考文献：

1.DunnPM.Thesearchforperinataldefinitionsandstandards.ActaPaediatrScandSuppl1985;319:7–16.(LevelIII)

2.WorldHealthOrganization.Reportofascientificgrouponhealthstatisticsmethodologyrelatedtoperinatalevents.DocumentICD/PE/74.4:1.Geneva:WHO;1974.(LevelIII)

3.HoffmanHJStarkCRLundinFEJrAshbrookofbirthweightgestationalageandfetalviabil-ityU.S.births1968.ObstetGynecolSurv1974;29:651–81.(LevelII-3)

4.BattagliaFCLubchencoLO.Apracticalclassificationofnewborninfantsbyweightandgestationalage.JPediatr1967;71:159–63.(LevelIII)

5.BeckmannCRLingFWBarzanskyBMHerbertWNLaubeDWSmithRP.Obstetricsandgynecology.6thed.

Baltimore(MD):LippincottWilliamsWilkins;2010.(LevelIII)

6.GalanHL.Timingdeliveryofthegrowth-restrictedPerinatol2011;35:262–9.(LevelIII)

7.PlatzENewmanR.DiagnosisofIUGR:traditionalbiometry.SeminPerinatol2008;32:140–7.(LevelIII)

8.XuHSimonetFLuoZC.Optimalbirthweightpercentilecut-offsindefiningsmall-orPaediatr2010;99:550–5.(LevelII-3)

9.AnanthCVVintzileosAM.Distinguishingpathologicalfromconstitutionalsmallforgestationalagebirthsinpopulation-basedstudies.EarlyHumDev2009;85:653–8.(LevelII-3)

10.BukowskiRUchidaTSmithGCMaloneFDBallRHNybergDAetal.Individualizednormsofoptimalfetalgrowth:fetalgrowthpotential.FirstandSecondTrimesterEvaluationofRisk(FASTER)ResearchConsortium.ObstetGynecol2008;111:1065–76.(LevelII-2)

11.GardosiJMulTMongelliMFaganD.AnalysisofbirthweightandgestationalageinantepartumJObstetGynaecol1998;105:524–30.(LevelIII)

12.OunstedMMoarVAScottA.Riskfactorsassociatedwithsmall-for-datesandlarge-for-datesinfants.BrJObstetGynaecol1985;92:226–32.(LevelII-3)

13.CunninghamFGCoxSMHarstadTWMasonRAPritchardJA.Chronicrenaldiseaseandpregnancyout-

come.AmJObstetGynecol1990;163:453–9.(LevelIII)

14.DuvekotJJCheriexECPietersFAMenheerePPSchoutenHJPeetersLL.Maternalvolumehomeostasis

inearlypregnancyinrelationtofetalgrowthrestriction.ObstetGynecol1995;85:361–7.(LevelIII)

15.Antiphospholipidsyndrome.PracticeBulletinNo.132.AmericanCollegeofObstetriciansandGynecologists.

ObstetGynecol2012;120:1514–21.(LevelIII)

16.FaccoFYouWGrobmanW.Geneticthrombophiliasandintrauterinegrowthrestriction:ameta-analysis.ObstetGynecol2009;113:1206–16.(LevelIII)

17.SaidJMHigginsJRMosesEKWalkerSPBorgAJMonaglePTetal.Inheritedthrombophiliapolymor-

phismsandpregnancyoutcomesinnulliparousGynecol2010;115:5–13.(LevelII-2)

18.SilverRMZhaoYSpongCYSibaiBWendelGJrWenstromKetal.ProthrombingeneG20210Amutation

andobstetriccomplications.EuniceKennedyShriverNationalInstituteofChildHealthandHumanDevelop-

mentMaternal–FetalMedicineUnits(NICHDMFMU)Network.ObstetGynecol2010;115:14–20.(LevelII-2)

19.BadaHSDasABauerCRShankaranSLesterBMGardCCetal.Lowbirthweightandpretermbirths:

etiologicfractionattributabletoprenataldrugPerinatol2005;25:631–7.(LevelII-3)

20.ShuXOHatchMCMillsJClemensJSusserM.Maternalsmokingalcoholdrinkingcaffeineconsumptionandfetalgrowth:resultsfromaprospectivestudy.Epidemi-ology1995;6:115–20.(LevelII-2)

21.MillsJLGraubardBIHarleyEERhoadsGGBerendesHW.Maternalalcoholconsumptionandbirthweight.

Howmuchdrinkingduringpregnancyissafe?JAMA1984;252:1875–9.(LevelII-2)

22.VirjiSK.Therelationshipbetweenalcoholconsumptionduringpregnancyandinfantbirthweight.Anepidemio-logicstudy.ActaObstetGynecolScand1991;70:303–8.(LevelII-3)

23.NaeyeRLBlancWLeblancWKhatameeMA.Fetalcomplicationsofmaternalheroinaddiction:abnormal

growthinfectionsandepisodesofstress.JPediatr1973;83:1055–61.(LevelIII)

24.FulrothRPhillipsBDurandDJ.Perinataloutcomeofinfantsexposedtococaineand/orheroininutero.AmJDisChild1989;143:905–10.(LevelII-3)

25.LittleBBSnellLMKleinVRGilstrapLCIII.Cocaineabuseduringpregnancy:maternalandfetalGynecol1989;73:157–60.(LevelII-3)

26.AntonovAN.ChildrenbornduringthesiegeofLeningradin1942.JPediatr1947;30:250–9.(LevelIII)

27.SmithCA.EffectsofmaternalundernutritionuponthenewborninfantinHolland(1944–1945).JPediatr1947;30:229–43.(LevelIII)

28.SayLGulmezogluAMHofmeyrGJ.Maternalnutrientsupplementationforsuspectedimpairedfetalgrowth.CochraneDatabaseofSystematicReviews2003Issue1.Art.No.:CD000148.DOI:10.1002/14651858.

CD000148.(Meta-analysis)

29.GuyerBMacDormanMFMartinJAPetersKDStrobinoDM.Annualsummaryofvitalstatistics-1997.Pedi-

atrics1998;102:1333–49.(LevelIII)

30.PowersWFKielyJL.Therisksconfrontingtwins:anationalperspective.AmJObstetGynecol1994;170:

456–61.(LevelII-3)

31.HoultonMCMarivateMPhilpottRH.Thepredictionoffetalgrowthretardationintwinpregnancy.BrJObstetGynaecol1981;88:264–73.(LevelII-3)

32.MauldinJGNewmanRB.Neurologicmorbidityassoci-atedwithmultiplegestation.FemalePatient1998;23(4):27–46.(LevelIII)

33.DenbowMLCoxPTaylorMHammalDMFiskNM.Placentalangioarchitectureinmonochorionictwinpreg-

nancies:relationshiptofetalgrowthfetofetaltransfusionsyndromeandpregnancyoutcome.AmJObstetGynecol2000;182:417–26.(LevelIII)

34.MaulikD.Fetalgrowthrestriction:theetiology.ClinObstetGynecol2006;49:228–35.(LevelIII)

35.BattinoDGranataTBinelliSCaccamoMLCaneviniMPCangerRetal.Intrauterinegrowthintheoffspringofepilepticmothers.ActaNeurolScand1992;86:555–7.(LevelIII)

36.MastroiacovoPBertolliniRLicataD.Fetalgrowthintheoffspringofepilepticwomen:resultsofanItalianmulticentriccohortstudy.ActaNeurolScand1988;78:110–4.(LevelII-2)

37.AvilesADiaz-MaqueoJCTalaveraAGuzmanRGarciaEL.Growthanddevelopmentofchildrenofmothers

treatedwithchemotherapyduringpregnancy:currentstatusof43children.AmJHematol1991;36:243–8.(Level

III)

38.HallJGPauliRMWilsonKM.Maternalandfetalsequelaeofanticoagulationduringpregnancy.AmJ

Med1980;68:122–40.(LevelIII)

39.CreasyRKResnikRIamsJDLockwoodCJMooreTReditors.CreasyandResnik’smaternal–fetalmedi-cine:principlesandpractice.6thed.Philadelphia(PA):SaundersElsevier;2009.(LevelIII)

40.DesaiMterKuileFONostenFMcGreadyRAsamoaKBrabinBetal.Epidemiologyandburdenofmalariainpregnancy.LancetInfectDis2007;7:93–104.(LevelIII)

41.DonnerCLiesnardCContentJBusineAAdercaJRodeschF.Prenataldiagnosisof52pregnanciesatriskforcongenitalcytomegalovirusinfection.ObstetGynecol1993;82:481–6.(LevelIII)

42.LambertJSWattsDHMofensonLStiehmERHarrisDRBethelJetal.RiskfactorsforpretermbirthlowbirthweightandintrauterinegrowthretardationininfantsborntoHIV-infectedpregnantwomenreceivingzidovudine.PediatricAIDSClinicalTrialsGroup185Team.AIDS2000;14:1389–99.(LevelI)

43.CailholJJourdainGCoeurSLTraisathitPBoonrodKPrommasSetal.AssociationoflowCD4cellcountandintrauterinegrowthretardationinThailand.PerinatalHIVPreventionTrialGroup.JAcquirImmuneDeficSyndr2009;50:409–13.(LevelI)

44.IqbalSNKriebsJHarmanCAlgerLKopelmanJTuranOetal.Predictorsoffetalgrowthinmaternal

HIVdisease.AmJPerinatol2010;27:517–23.(LevelII-3)

45.EydouxPChoisetALePorrierNThepotFSzpiro-TapiaSAllietJetal.Chromosomalprenataldiagnosis:studyof936casesofintrauterineabnormalitiesafterultra-soundassessment.PrenatDiagn1989;9:255–69.(LevelIII)

46.WolstenholmeJRooneyDEDavisonEV.ConfinedplacentalmosaicismIUGRandadversepregnancyoutcome:acontrolledretrospectivecollaborativesurvey.PrenatDiagn1994;14:345–61.(LevelII-2)

47.Wilkins-HaugLRobertsDJMortonCC.Confinedplacentalmosaicismandintrauterinegrowthretardation:acase-controlanalysisofplacentasatdelivery.AmJObstetGynecol1995;172:44–50.(LevelIII)

48.KhouryMJEricksonJDCorderoJFMcCarthyBJ.Congenitalmalformationsandintrauterinegrowthretardation:apopulationstudy.Pediatrics1988;82:83–90.(LevelII-3)

49.WallensteinMBHarperLMOdiboAORoehlKALongmanREMaconesGAetal.Fetalcongenitalheartdiseaseandintrauterinegrowthrestriction:aretrospectivecohortstudy.JMaternFetalNeonatalMed2012;25:662–5.(LevelII-3)

50.MalikSClevesMAZhaoWCorreaAHobbsbetweencongenitalheartdefectsandsmallforgestationalage.NationalBirthDefectsPreventionStudy.Pediatrics2007;119:e976–82.(LevelII-3)

51.RaynorBDRichardsD.Growthretardationinfetuseswithgastroschisis.JUltrasoundMed1997;16:13–6.(LevelIII)

52.SalafiaCMMiniorVKPezzulloJCPopekEJRosenkrantzTSVintzileosAM.Intrauterinegrowthrestrictionininfantsoflessthanthirty-twoweeks’gestation:associatedplacentalpathologicfeatures.AmJObstetGynecol1995;173:1049–57.(LevelII-3)

53.LauriniRLaurinJMarsalK.Placentalhistologyandfetalbloodflowinintrauterinegrowthretardation.ActaObstetGynecolScand1994;73:529–34.(LevelIII)

54.ShanklinDR.Theinfluenceofplacentallesionsonthenewborninfant.PediatrClinNorthAm1970;17:25–42.(LevelII-3)

55.AnanthCVDemissieKSmulianJCVintzileosamongplacentapreviafetalgrowthrestrictionandpretermdelivery:apopulation-basedstudy.Ob-stetGynecol2001;98:299–306.(LevelII-3)

56.AnanthCVWilcoxAJ.PlacentalabruptionandperinatalmortalityintheUnitedStates.AmJEpidemiol2001;153:332–7.(LevelII-3)

57.ChapmanMGFurnessETJonesWRSheatJH.Significanceoftheultrasoundlocationofplacentalsiteinearlypregnancy.BrJObstetGynaecol1979;86:846–8.(LevelIII)

58.HarperLMOdiboAOMaconesGACraneJPCahillAG.Effectofplacentapreviaonfetalgrowth.AmJObstetGynecol2010;203:330.e1–e5.(LevelII-2)

59.PollackRNDivonMY.Intrauterinegrowthretardation:definitionclassificationandetiology.ClinObstetGynecol1992;35:99–107.(LevelIII)

60.ThummalaMRRajuTNLangenbergP.Isolatedsingleumbilicalarteryanomalyandtheriskforcongenitalmalformations:ameta-analysis.JPediatrSurg1998;33:580–5.(Meta-Analysis)

61.HeifetzSA.Singleumbilicalartery.Astatisticalanalysisof237autopsycasesandreviewoftheliterature.PerspectPediatrPathol1984;8:345–78.(LevelIII)

62.ResnikR.Intrauterinegrowthrestriction.ObstetGynecol2002;99:490–6.(LevelIII)

63.PallottoEKKilbrideHW.Perinataloutcomeandlaterimplicationsofintrauterinegrowthrestriction.ClinObstetGynecol2006;49:257–69.(LevelIII)

64.BarkerDJ.Adultconsequencesoffetalgrowthrestriction.ClinObstetGynecol2006;49:270–83.(LevelIII)

65.ClaussonBCnattingiusSAxelssonO.Outcomesofpost-termbirths:theroleoffetalgrowthrestrictionandmalformations.ObstetGynecol1999;94:758–62.(LevelII-3)

66.GetahunDAnanthCVKinzlerWL.Riskfactorsforantepartumandintrapartumstillbirth:apopulation-basedstudy.AmJObstetGynecol2007;196:499–507.(LevelII-3)

67.EgoASubtilDGrangeGThiebaugeorgesOSenatMVVayssiereCetal.Customizedversuspopulationbasedbirthweightstandardsforidentifyinggrowthrestrictedinfants:aFrenchmulticenterstudy.AmJObstetGynecol2006;194:1042–9.(LevelII-3)

68.VerganiPRoncagliaNLocatelliAAndreottiCCrippaIPezzulloJCetal.Antenatalpredictorsofneonataloutcomeinfetalgrowthrestrictionwithabsentend-diastolic

flowintheumbilicalartery.AmJObstetGynecol2005;193:1213–8.(LevelII-3)

69.McIntireDDBloomSLCaseyBMLevenoKJ.Birthweightinrelationtomorbidityandmortalityamongnewborninfants.NEnglJMed1999;340:1234–8.(LevelII-2)

70.HartungJKalacheKDHeynaCHelingKSKuhligMWauerRetal.Outcomeof60neonateswhohadAREDflowprenatallycomparedwithamatchedcontrolgroupofappropriate-for-gestationalagepretermneonates.Ultra-soundObstetGynecol2005;25:566–72.(LevelII-2)

71.ShandAWHornbuckleJNathanEDickinsonJEFrenchNP.SmallforgestationalagepreterminfantsandrelationshipofabnormalumbilicalarteryDopplerbloodflowtoperinatalmortalityandneurodevelopmentaloutcomes.AustNZJObstetGynaecol2009;49:52–8.(LevelII-2)

72.JonesRARobertonNR.Problemsofthesmall-for-datesbaby.ClinObstetGynaecol1984;11:499–524.(LevelIII)

73.AlkalayALGrahamJMJrPomeranceJJ.Evaluationofneonatesbornwithintrauterinegrowthretardation:reviewandpracticeguidelines.JPerinatol1998;18:142–51.(LevelIII)

74.KnoxAJSadlerLPattisonNSMantellCDMullinsP.Anobstetricscoringsystem:itsdevelopmentandapplicationinobstetricmanagement.ObstetGynecol1993;81:195–9.(LevelII-3)

75.LeesonSAzizN.CustomisedfetalgrowthJObstetGynaecol1997;104:648–51.(LevelIII)

76.JahnARazumOBerleP.Routinescreeningforintra-uterinegrowthretardationinGermany:lowsensitivityandquestionablebenefitfordiagnosedcases.ActaObstetGynecolScand1998;77:643–8.(LevelII-3)

77.KeanLHLiuDT.Antenatalcareasascreeningtoolforthedetectionofsmallforgestationalagebabiesinthelowriskpopulation.JObstetGynaecol1996;16:77–82.(LevelII-3)

78.SparksTNChengYWMcLaughlinBEsakoffTFCaugheyAB.Fundalheight:ausefulscreeningtoolforfetalgrowth?JMaternFetalNeonatalMed2011;24:708–12.(LevelII-2)

79.GoetzingerKRTuuliMGOdiboAORoehlKAMa-conesGACahillAG.Screeningforfetalgrowthdisor-dersbyclinicalexamintheeraofobesity.JPerinatol2012;DOI:10.1038/;10.1038/(LevelII-2)

80.HadlockFPHarristRBSharmanRSDeterRLParkSK.Estimationoffetalweightwiththeuseofheadbodyandfemurmeasurements––aprospectivestudy.AmJObstetGynecol1985;151:333–7.(LevelIII)

81.HadlockFPHarristRBCarpenterRJDeterRLParkSK.Sonographicestimationoffetalweight.Thevalueoffemurlengthinadditiontoheadandabdomenmeasure-ments.Radiology1984;150:535–40.(LevelIII)

82.ChienPFOwenPKhanKS.Validityofultrasoundestimationoffetalweight.ObstetGynecol2000;95:856–60.(LevelII-2)

83.DudleyNJ.Asystematicreviewoftheultrasoundestimationoffetalweight.UltrasoundObstetGynecol2005;25:80–9.(LevelIII)

84.BerkleyEChauhanSPAbuhamadA.Dopplerassessmentofthefetuswithintrauterinegrowthrestriction.SocietyforMaternal-FetalMedicinePublicationsCommittee[publishederratumappearsinAmJObstetGynecol2012;206:508].AmJObstetGynecol2012;206:300–8.(LevelIII)

85.KingdomJCBurrellSJKaufmannP.PathologyandclinicalimplicationsofabnormalumbilicalarteryDopplerwaveforms.UltrasoundObstetGynecol1997;9:271–86.(LevelIII)

86.PardiGCetinIMarconiAMLanfranchiABozzettiPFerrazziEetal.Diagnosticvalueofbloodsamplinginfetuseswithgrowthretardation.NEnglJMed1993;328:692–6.(LevelIII)

87.NicolaidesKHBilardoCMSoothillPWCampbellofenddiastolicfrequenciesinumbilicalartery:asignoffetalhypoxiaandacidosis.BMJ1988;297:1026–7.(LevelIII)

88.BilardoCMNicolaidesKHCampbellS.Dopplermeasurementsoffetalanduteroplacentalcirculations:relationshipwithumbilicalvenousbloodgasesmeasuredatcordocentesis.AmJObstetGynecol1990;162:115–20.(LevelIII)

89.GilesWBisitsA.ClinicaluseofDopplerultrasoundinpregnancy:informationfromsixrandomisedtrials.FetalDiagnTher1993;8:247–55.(LevelIII)

90.AlfirevicZStampalijaTGyteGML.FetalandumbilicalDopplerultrasoundinnormalpregnancy.CochraneDatabaseofSystematicReviews2010Issue8.Art.No.:CD001450.DOI:10.1002/14651858.(Meta-analysis)

91.RizzoGCapponiAArduiniDRomaniniC.ThevalueoffetalarterialcardiacandvenousflowsinpredictingpHandbloodgasesmeasuredinumbilicalbloodatcordocentesisingrowthretardedfetuses.BrJObstetGynaecol1995;102:963–9.(LevelIII)

92.HecherKSnijdersRCampbellSNicolaidesK.Fetalvenousintracardiacandarterialbloodflowmeasure-mentsinintrauterinegrowthretardation:relationshipwithfetalbloodgases.AmJObstetGynecol1995;173:10–5.(LevelIII)

93.BaschatAA.Dopplerapplicationinthedeliverytimingofthepretermgrowth-restrictedfetus:anotherstepintherightdirection.UltrasoundObstetGynecol2004;23:111–8.(LevelIII)

94.GhidiniA.Doppleroftheductusvenosusinseverepretermfetalgrowthrestriction:atestinsearchofapurpose?ObstetGynecol2007;109:250–2.(LevelIII)

95.IrwinJCSuenLFMartinaNAMarkSPGiudiceLC.RoleoftheIGFsystemintrophoblastinvasionandpreeclampsia.HumReprod1999;14(suppl2):90–6.(LevelIII)

96.SpencerKCowansNJAvgidouKMolinaFNicolaidesKH.First-trimesterbiochemicalmarkersofaneuploidyandthepredictionofsmall-for-gestationalagefetuses.UltrasoundObstetGynecol2008;31:15–9.(LevelII-3)

97.KrantzDGoetzlLSimpsonJLThomEZacharyJHallahanTWetal.Associationofextremefirsttrimesterfreehumanchorionicgonadotropin-betapregnancy-associatedplasmaproteinAandnuchaltranslucencywithintrauterinegrowthrestrictionandotheradversepregnancyoutcomes.FirstTrimesterMaternalSerumBiochemistryandFetalNuchalTranslucencyScreening(BUN)StudyGroup.AmJObstetGynecol2004;191:1452–8.(LevelII-2)

98.GoetzlLKrantzDSimpsonJLSilverRKZacharyJMPergamentEetal.Pregnancy-associatedplasmaproteinAfreebeta-hCGnuchaltranslucencyandriskofpreg-nancyloss.ObstetGynecol2004;104:30–6.(LevelII-2)

99.DugoffL.First-andsecond-trimestermaternalserummarkersforaneuploidyandadverseobstetricforMaternal-FetalMedicine.ObstetGynecol2010;115:1052–61.(LevelII-2)

100.ZhongYTuuliMOdiboAO.First-trimesterassessmentofplacentafunctionandthepredictionofpreeclampsiaandintrauterinegrowthrestriction.PrenatDiagn2010;30:293–308.(LevelIII)

101.PoonLCStratievaVPirasSPiriSNicolaidesKH.Hypertensivedisordersinpregnancy:combinedscreeningbyuterinearteryDopplerbloodpressureandserumPAPP-Aat11–13weeks.PrenatDiagn2010;30:216–23.(LevelII-2)

102.GoetzingerKRSinglaAGerkowiczSDickeJMGrayDLOdiboAO.Predictingtheriskofpre-eclampsiabetween11and13weeks’gestationbycombiningmaternalcharacteristicsandserumanalytesPAPP-Aandfreebeta-hCG.PrenatDiagn2010;30:1138–42.(LevelII-3)

103.MorrisRKMalinGRobsonSCKleijnenJZamoraJKhanKS.FetalumbilicalarteryDopplertopredictcompromiseoffetal/neonatalwellbeinginahigh-riskpop-ulation:systematicreviewandbivariatemeta-analysis.Ultra-soundObstetGynecol2011;37:135–42.(Meta-analysis)

104.SilverRMVarnerMWReddyUGoldenbergRPinarHConwayDetal.Work-upofstillbirth:areviewoftheevidence.AmJObstetGynecol2007;196:433–44.(LevelIII)

105.KafatosAGVlachonikolisIGCodringtonCA.Nutritionduringpregnancy:theeffectsofaneducationalinterventionprograminGreece.AmJClinNutr1989;50:970–9.(LevelII-1)

106.KhouryJHenriksenTChristophersenBTonstadofacholesterol-loweringdietonmaternalcordandneonatallipidsandpregnancyoutcome:arandomizedclinicaltrial.AmJObstetGynecol2005;193:1292–301.(LevelI)

107.SteegersEAVanLakwijkHPJongsmaHWFastJHDeBooTEskesTKetal.(Patho)physiologicalimplicationsofchronicdietarysodiumrestrictionduringpregnancy;

alongitudinalprospectiverandomizedstudy.BrJObstetGynaecol1991;98:980–7.(LevelI)

108.Pena-RosasJPDe-RegilLMDowswellTViterioralironsupplementationduringpregnancy.CochraneDatabaseofSystematicReviews2012Issue12.Art.No.:CD004736.DOI:10.1002/14651858.(LevelIII)

109.MoriROtaEMiddletonPTobe-GaiRMahomedKBhuttaZA.Zincsupplementationforimprovingpregnancyandinfantoutcome.CochraneDatabaseofSystematicReviews2012Issue7.Art.No.:CD000230.DOI:10.1002/14651858.(Meta-analysis)

110.HofmeyrGJLawrieTAAtallahANDuleyL.Calciumsupplementationduringpregnancyforpreventinghypertensivedisordersandrelatedproblems.CochraneDatabaseofSystematicReviews2010Issue8.Art.No.:CD001059.DOI:10.1002/14651858.(Meta-analysis)

111.OtaETobe-GaiRMoriRFarrarD.Antenataldietaryadviceandsupplementationtoincreaseenergyandproteinintake.CochraneDatabaseofSystematicReviews2012Issue9.Art.No.:CD000032.DOI:10.1002/14651858.(Meta-analysis)

112.MakridesMCrowtherCA.Magnesiumsupplementationinpregnancy.CochraneDatabaseofSystematicReviews2001Issue4.Art.No.:CD000937.DOI:10.1002/14651858.CD000937.(Meta-analysis)

113.De-RegilLMPalaciosCAnsaryAKulierRPena-Ro-sasJP.VitaminDsupplementationforwomenduringpregnancy.CochraneDatabaseofSystematicReviews2012Issue2.Art.No.:CD008873.DOI:10.1002/14651858.(Meta-analysis)

114.SayLGulmezogluAMHofmeyrGJ.Bedrestinhospitalforsuspectedimpairedfetalgrowth.CochraneDatabaseofSystematicReviews1996Issue1.Art.No.:CD000034.DOI:10.1002/14651858.CD000034.(Meta-analysis)

115.BujoldERobergeSLacasseYBureauMAudibertFMarcouxSetal.Preventionofpreeclampsiaandintra-uterinegrowthrestrictionwithaspirinstartedinearlypregnancy:ameta-analysis.ObstetGynecol2010;116:402–14.(Meta-analysis)

116.PelegDKennedyCMHunterSK.Intrauterinegrowthrestriction:identificationandmanagement.AmFamPhy-sician1998;58:453–60466–7.(LevelIII)

117.GulmezoluMdeOnisMVillarJ.Effectivenessofin-terventionstopreventortreatimpairedfetalgrowth.ObstetGynecolSurv1997;52:139–49.(LevelIII)

118.LeitichHEgarterCHussleinPKaiderASchempermeta-analysisoflowdoseaspirinforthepreventionofintrauterinegrowthretardation.BrJObstetGynaecol1997;104:450–9.(Meta-analysis)

119.Bahado-SinghROLynchLDerenOMorrotiRCopelJAMahoneyMJetal.First-trimestergrowthrestrictionandfetalaneuploidy:theeffectoftypeofaneuploidyandgestationalage.AmJObstetGynecol1997;176:976–80.(LevelII-3)

120.SassoonDACastroLCDavisJLHobelCJ.Perinataloutcomeintripletversustwingestations.ObstetGynecol1990;75:817–20.(LevelII-2)

121.AlexandrJMHammondKRSteinkampfMP.Multifetalreductionofhigh-ordermultiplepregnancy:comparisonofobstetricaloutcomewithnonreducedtwinSteril1995;64:1201–3.(LevelIII)

122.SilverRHelfandBTRussellTLRaginAShollJSMacGregorSN.Multifetalreductionincreasestheriskofpretermdeliveryandfetalgrowthrestrictionintwins:acase-controlstudy.FertilSteril1997;67:30–3.(LevelII-2)

123.Multiplegestation:complicatedtwintripletandhigh-ordermultifetalpregnancy.ACOGPracticeBulletinAmericanCollegeofObstetriciansandGynecologists.ObstetGynecol2004;104:869–83.(LevelIII)

124.MachinA.Velamentouscordinsertioninmonochorionictwingestation.Anaddedriskfactor.JReprodMed1997;42:785–9.(LevelIII)

125.DivonMYChamberlainPFSiposLManningFAPlattLD.Identificationofthesmallforgestationalagefetuswiththeuseofgestationalage-independentindicesoffetalgrowth.AmJObstetGynecol1986;155:1197–201.(LevelII-3)

126.MongelliMEkSTambyrajiaR.Screeningforfetalgrowthrestriction:amathematicalmodeloftheeffectoftimeintervalandultrasounderror.ObstetGynecol1998;92:908–12.(LevelII-3)

127.ArabinBBergmannPLSalingE.Simultaneousassessmentofbloodflowvelocitywaveformsinuteroplacentalvesselstheumbilicalarterythefetalaortaandthefetalcommoncarotidartery.FetalTher1987;2:17–26.(LevelIII)

128.LeesCCMarlowNvanWassenaer-LeemhuisAArabinBBilardoCMBrezinkaCetal.2yearneurodevelop-mentalandintermediateperinataloutcomesininfantswithverypretermfetalgrowthrestriction(TRUFFLE):arandomisedtrial.TRUFFLEstudygroup[publishederratumappearsinLancet2015;385:2152].Lancet2015;385:2162–72.(LevelI)

129.VeilleJCKanaanC.DuplexDopplerultrasonographicevaluationofthefetalrenalarteryinnormalandabnormalfetuses.AmJObstetGynecol1989;161:1502–7.(LevelIII)

130.GramelliniDFolliMCRaboniSVadoraEMerialdiDopplerratioasapredictorofadverseperinataloutcome.ObstetGynecol1992;79:416–20.(LevelIII)

131.BahadoSinghROKovanciEJeffresAOzUDerenOCopelJetal.TheDopplercerebroplacentalratioandperinataloutcomeinintrauterinegrowthrestriction.AmJObstetGynecol1999;180:750–6.(LevelII-3)

132.Arandomisedtrialoftimeddeliveryforthecompromisedpretermfetus:shorttermoutcomesandBayesianinterpretation.GRITStudyGroup.BJOG2003;110:27–32.(LevelI)

133.ThorntonJGHornbuckleJVailASpiegelhalterDJLeveneM.Infantwellbeingat2yearsofageintheGrowthRestrictionInterventionTrial(GRIT):multicentredrandomisedcontrolledtrial.GRITstudygroup.Lancet2004;364:513–20.(LevelI)

134.WalkerDMMarlowNUpstoneLGrossHHornbuckleJVailAetal.TheGrowthRestrictionInterventionTrial:long-termoutcomesinarandomizedtrialoftimingofdeliveryinfetalgrowthrestriction.AmJObstetGynecol2011;204:34.e1–e9.(LevelI)

135.BoersKEVijgenSMBijlengaDvanderPostJABekedamDJKweeAetal.Inductionversusexpectantmonitoringforintrauterinegrowthrestrictionatterm:randomisedequivalencetrial(DIGITAT).DIGITAStudyGroup.BMJ2010;341:c7087.(LevelI)

136.SpongCYMercerBMD’AltonMKilpatrickSBlack-wellSSaadeG.Timingofindicatedlate-pretermandearly-termbirth.ObstetGynecol2011;118:323–33.(LevelIII)

137.Medicallyindicatedlate-pretermandearly-termdeliveries.ACOGCommitteeOpinionNo.764.AmericanCollegeofObstetriciansandGynecologists.ObstetGynecol2019;133:151–55.(LevelIII)

138.BerkleyEChauhanSPAbuhamadA.DopplerassessmentofthefetuswithintrauterinegrowthforMaternal-FetalMedicinePublicationsCommittee[publishederrataappearinAmJObstetGynecol2015;212:246;AmJObstetGynecol2012;206:508].AmJObstetGynecol2012;206:300–8.(LevelIII)

139.Antenatalcorticosteroidsrevisited:repeatcourses.NIHConsensStatement2000;17:1–18.(LevelIII)

140.RobertsDDalzielSR.Antenatalcorticosteroidsforacceleratingfetallungmaturationforwomenatriskofpretermbirth.CochraneDatabaseofSystematicReviews2006Issue3.Art.No.:CD004454.DOI:10.1002/14651858.(Meta-analysis)

141.Effectofcorticosteroidsforfetalmaturationonperinataloutcomes.NIHConsensStatement1994;12:1–24.(LevelIII)

142.Gyamfi-BannermanCThomEABlackwellSCTitaATReddyUMSaadeGRetal.Antenatalbetamethasoneforwomenatriskforlatepretermdelivery.NICHDMaternal-FetalMedicineUnitsNetwork.NEnglJMed2016;374:1311–20.(LevelI)

143.AntenatalcorticosteroidtherapyforfetalOpinionNo.713.AmericanCollegeofOb-stetriciansandGynecologists.ObstetGynecol2017;130:e102–9.(LevelIII)

144.CrowtherCAVerkuylDANeilsonJPBannermanCAshurstHM.Theeffectsofhospitalizationforrestonfetalgrowthneonatalmorbidityandlengthofgestationintwinpregnancy.BrJObstetGynaecol1990;97:872–7.(LevelI)

145.MarretSMarpeauLZupan-SimunekVEurinDLev-equeCHellotMFetal.Magnesiumsulphategivenbeforevery-pretermbirthtoprotectinfantbrain:therand-omisedcontrolledPREMAGtrial*.PREMAGTrialGroup.BJOG2007;114:310–8.(LevelI)

146.RouseDJHirtzDGThomEVarnerMWSpongCYMercerBMetal.Arandomizedcontrolledtrialofmagnesiumsulfateforthepreventionofcerebralpalsy.EuniceKennedyShriverNICHDMaternal–FetalMedicineUnitsNetwork.NEnglJMed2008;359:895–905.(LevelI)

147.Magnesiumsulfatebeforeanticipatedpretermbirthforneuroprotection.CommitteeOpinionNo.455.AmericanCollegeofObstetriciansandGynecologists.ObstetGyne-col2010;115:669–71.(LevelIII)